Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar ...

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

Abatacept, a CTLA4–Fc fusion protein that modulates T-cell activation, has been developed for the treatment of rheumatoid arthritis. Tay et al. evaluated the effect of abatacept on vaccination ...

Weekly injections of the drug, abatacept, cut the risk of developing the auto-immune disease by 80 per cent during a trial.

Among the launches are Semaglutide in Canada, with a market size of $2 billion, and Abatacept in the US, with a market size of $2.8 billion. Semaglutide, a diabetic injection, goes off-patent in ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully ...